2. As of noon trading, GlaxoSmithKline ( GSK) is up $0.48 (1.1%) to $44.16 on average volume Thus far, 1.5 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $44.15-$44.41 after having opened the day at $44.39 as compared to the previous trading day's close of $43.68.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $113.3 billion and is part of the health care sector. The company has a P/E ratio of 13.5, below the S&P 500 P/E ratio of 17.7. Shares are down 1.7% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk